Could fewer infusions tame thyroid eye disease just as well?
NCT ID NCT07308964
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) to the standard 8-infusion course in people with active thyroid eye disease (TED). The goal is to see if those who respond well early can safely stop treatment sooner with the same benefits. The study will enroll 40 participants who show significant improvement after 4 infusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.